What were the key takeaways from Evolent Health's earnings call?

What is the market's earnings forecast for Evolent Health next quarter?

What guidance did Evolent Health's management provide for the next earnings period?

Did Evolent Health beat or miss consensus estimates last quarter?

What is Evolent Health's latest dividend and current dividend yield?

What were the key takeaways from Evolent Health’s earnings call?

What is the revenue and EPS growth rate for Evolent Health year over year?

What factors drove the changes in Evolent Health's revenue and profit?

- **Revenue Growth**: 30% 2026 forecast to $2.5B, with oncology driving 65% of revenue.
- **Margin Targets**: 7%-10% long-term margin on Performance Suite, with 2026 MER 93% (conservative reserving).
- **Cost Savings**: $50M+ 2026 savings from AI/automation, reducing SG&A and claims processing.
- **New Contracts**: Highmark deal ($550M+ 2026) and state expansions highlight strategic focus on enhanced Performance Suite model.
- **Risk Management**: 10% target margin with downside protection, 7% swing potential in EBITDA based on MER performance.


**【CEO Summary Section】**
- **Q4 2025 Results**: Revenue and adjusted EBITDA landed in the upper half of guidance, with strong execution across 3 pillars: organic growth, profitability, and capital allocation.
- **2026 Outlook**: Forecasted 30% revenue growth to $2.5B, driven by oncology (65% of revenue vs. 36% in 2025) and new contracts. Adjusted EBITDA guidance of $125M midpoint, with Q4 2026 run rate >$150M.
- **Contract Renegotiations**: 90% of Performance Suite revenue under enhanced model with 10% target margin (vs. 15% prior). New contracts include Highmark ($550M+ 2026 revenue) and state expansions.
- **Efficiency Initiatives**: Exceeded $20M annualized savings in Q4 2025, targeting $50M+ in 2026 through AI/automation (e.g., 16pt increase in MRI auto-authorization rates).

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: Revenue $469M, adjusted EBITDA $37.8M (vs. $35M midpoint). FY2025 adj. EBITDA $141M (excluding ECP). Cash flow $39M, ending with $782M net debt.
- **2026 Guidance**: Revenue $2.4B-$2.6B, adj. EBITDA $110M-$140M. Key drivers: $900M new Performance Suite revenue (MER 103%), $40M headwind from exchange membership decline, and $50M cost savings.
- **MER Dynamics**: 2025 MER 89% (excl. ECP), 2026 midpoint MER 93% due to new contracts. Long-term target 7%-10% margin on $2.2B+ Performance Suite revenue.
- **Reserving Approach**: Conservative reserving for new contracts (e.g., $13M IBNR impact) leading to 70% EBITDA weighted to H2 2026.

**【Q&A Highlights】**
- **Reserving and New Contracts**: CFO explains $103% MER for 2026 new contracts reflects conservative reserving, with potential 7% swing in EBITDA based on MER performance.
- **Oncology Trends**: 2026 oncology trend expected to match 2025 levels (~15%), with contractual protections for uncontrollable factors.
- **Pipeline and Growth**: CEO highlights balanced pipeline of Performance Suite and Tech/Services deals, with 2026 growth focused on existing contracts rather than new signings.
- **Capital Allocation**: Prioritizes debt paydown (net debt $782M) while investing in AI, clinical programs, and sales to drive long-term margin expansion.
- **Exchange Impact**: 40%+ exchange membership decline expected, but offset by new business wins and focus on Medicare Advantage growth.


Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

- **Revenue Beats Expectations**: Q3 revenue $479.5 million, full-year guidance $1.87-1.88 billion.
- **$500M New Contracts**: Blue Cross oncology deal and provider partnership add $550M 2026 revenue, $750M+ pipeline.
- **Margin Expansion**: 23% EBITDA growth to $39M; 90% of 2026 Performance Suite revenue protected.
- **Debt Reduction**: $100M debt paydown from Care Partners sale, lowering interest costs by $10M annually.
- **Oncology Growth**: Targeting 15% market share, $15B+ annual opportunity. Navigation program reduces inpatient utilization by 40%.
- **Risk Management**: 10% target margins for new contracts, conservative 2026 EBITDA outlook due to exchange uncertainty.

**【CEO Summary Section】**
- **Q3 Revenue Growth**: $479.5 million, at the top of guidance range, with full-year revenue projected between $1.87 billion and $1.88 billion.
- **New Contracts**: Signed two major deals contributing $500 million annually, including a Blue Cross plan for oncology care and a provider-sponsored health plan partnership. Total 2026 pipeline exceeds $650 million.
- **Margin Expansion**: Adjusted EBITDA of $39 million (23% YoY growth), with 90% of 2026 Performance Suite revenue protected by prevalence adjustments and risk corridors.
- **Capital Allocation**: Sale of Evolent Care Partners to reduce debt by $100 million, lowering annual interest costs by $10 million.
- **Long-Term Outlook**: Targeting 15% oncology market penetration, representing $15 billion+ annual opportunity. New contracts expected to generate $75 million+ EBITDA at maturity.

**【CFO Financial Commentary】**
- **Q3 Financials**: Revenue $480 million (8% sequential growth), adjusted EBITDA $39 million. Sequential growth driven by higher fee launches in oncology and musculoskeletal care.
- **Cash Flow**: $15 million cash from operations, offset by $40 million in debt refinancing. Year-end net debt projected at $805-$840 million.
- **Utilization Trends**: 11% oncology cost trend, stable in Medicaid/Medicare but elevated in exchanges due to pre-2026 benefit rush. Conservative reserving maintained.
- **Balance Sheet**: $116.7 million cash, $47.5 million revolver availability. No debt maturities until 2029.

**【Q&A Key Highlights】**
- **Contract Margins**: New contracts target 10% mature margins, with narrower risk corridors and value-sharing with partners.
- **2026 EBITDA Outlook**: Uncertain due to exchange membership decline (15%-65% range). Base case assumes no growth; upside if exchange subsidies extended.
- **MA Enrollment**: Potential for share gains among large customers, benefiting tech/services suite. CMS forecasts 3% MA contraction.
- **Oncology Navigation**: Reduces inpatient utilization by 40%, with 90% patient satisfaction. Rolling out to additional markets in 2026.
- **Provider Partnership**: American Oncology Network collaboration aims to eliminate utilization management, integrating Evolent's care navigation into EMRs.
- **AI Efficiency**: On track for $20 million annual savings from AI-driven authorization workflows.


Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript

- **Q2 Strong Performance**: $37.5M EBITDA, 4 new contracts, and $250M+ pipeline highlight execution strength. Aetna partnership in Medicare Advantage signals strategic win.
- **AI-Driven Efficiency**: 11% efficiency improvement from AI tools, targeting 80% auto-approval by 2026, with $20M EBITDA upside.
- **2026 Growth Ambition**: $2.5+ billion revenue target, 80% new business in Medicare, and 20%+ EBITDA growth driven by oncology and AI.
- **Risks & Caution**: Exchange business faces 2026 headwinds (5% membership decline could cost $8-10M EBITDA), offset by disciplined contract structuring and Medicare focus.

**【CEO Summary Section】**
- **Q2 Performance Highlights**: Achieved adjusted EBITDA of $37.5 million, exceeding expectations, with four new revenue agreements and a pipeline of $250 million+ in new business expected to go live by Q1 2026.
- **New Partnerships**: Announced Aetna partnership for 250,000 Medicare Advantage members in Florida, expanding oncology and cardiology solutions. Three new Technology & Services agreements added 400,000+ members across cardiology, MSK, and radiation oncology.
- **AI & Automation Progress**: Integrated AI-driven review tools, improving efficiency by 11% in Q2, targeting 80% of authorization volume to be auto-approved by 2026. Projected $20 million annualized EBITDA improvement from AI initiatives.
- **Growth Outlook**: Confident in 20%+ annual EBITDA growth, driven by $2.5+ billion revenue target for 2026, with 80% of new business in Medicare Advantage.

**【CFO Financial Commentary】**
- **Q2 Financials**: Revenue of $444 million (vs. $11M below midpoint due to timing delays), adjusted EBITDA of $37.5 million. Oncology trend at 10.5% (vs. 12% forecast), benefiting from adherence to best evidence medicine.
- **Cash Flow Management**: Ended Q2 with $151 million cash, expecting $40 million in cash from operations for Q3-Q4. Addressed payment variability through contract amendments, reducing DSO risk.
- **2025 Guidance Update**: Adjusted EBITDA revised to $140-165 million (vs. prior $130-150M), with Q3 EBITDA of $34-42 million. Full-year revenue updated to $1.85-1.88 billion.

**【Q&A Key Highlights】**
- **Aetna Partnership**: Expected to launch Q1 2026, with margin ramp consistent with 10% target over two years. Focus on data exchange and clinical integration to enable scalability.
- **Contract Structuring**: New Performance Suite contracts include enhanced protections (e.g., corridors, data flow requirements), balancing risk and upside.
- **Exchange Business Risks**: Anticipate 2026 exchange membership decline due to subsidy expiration, with $8-10 million EBITDA headwind if membership drops 5%.
- **Pipeline Visibility**: $1 billion+ weighted pipeline across Tech & Services and Performance Suite, with 80%+ in Medicare Advantage and oncology-focused specialties.
- **Oncology Trend**: 10.5% YTD trend (vs. 12% forecast), driven by elevated utilization but favorable claims development. 2025 guidance assumes 12% back-half trend, incorporating potential exchange benefits rush.

Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 at high end of guidance ($483.6M), driven by new contracts and oncology PMPM +20%+.
- **Oncology Efficiency**: Cost trend at ~12% (vs. 12% guide), aided by AI automation reducing review time by 30%.
- **AI Expansion**: Full automation potential in 2026, targeting 300,000 members with Careology app for real-time symptom management.
- **Pipeline Strength**: Performance Suite pipeline doubles YoY, with new contract model driving 89% employee engagement.
- **Policy Resilience**: <5% Medicaid impact from work requirements, no 2025 effect; MSSP support reinforces value-based care.

**【CEO Organic Growth Overview】**
- **New Contracts Expansion**: Secured five new revenue agreements across oncology, surgical, and musculoskeletal conditions, adding ~$10M annualized revenue and 1M new lives on the platform.
- **Performance Suite Pipeline**: Record-high pipeline with updated contract model (narrow corridor) driving sales success; oncology penetration remains under 5% of total opportunity.
- **AI Automation Progress**: Deployed AI on 200,000 reviews, improving clinician satisfaction and response times; UM share of value creation expected to drop from 15% to <10%.
- **Oncology Navigation Launch**: Integrated Careology app and oncology care partner assets, targeting 300,000 members by end-May with early examples of reduced hospital visits and improved adherence.

**【CFO Financial & Trend Analysis】**
- **Q1 Revenue**: $483.6M (high end of guidance), driven by $55M one-time gross-to-net conversion; adjusted EBITDA neutral.
- **Medical Cost Trends**: Oncology trend at ~12% (lower than expected), aided by 20%+ same-store PMPM increases; cardiology tracking as expected.
- **Cash Flow**: Generated $4.6M in Q1, with $40M+ expected for 2025 after restructuring payments and OCP asset purchase.
- **Policy Risks**: Medicaid work requirements could impact <5% of membership ($8-10M EBITDA), but no 2025 impact anticipated.

**【Q&A Key Takeaways】**
- **PMPM Trends**: Sequential decline in Performance Suite PMPM due to MA mix shift, but new MA oncology go-live expected to lift PMPM later in 2025.
- **Oncology Cost Drivers**: Lower disease prevalence and clinical management success (e.g., pathway adherence +20pp) contributing to trend moderation.
- **AI Impact**: Automation reducing review time by 30%+ and enabling real-time authorizations, with full automation potential in 2026.
- **Commercial Demand**: Strong interest in surgical and oncology solutions, with no incremental sales capacity needed for employer market penetration.
- **Competitive Position**: Performance Suite pipeline doubles YoY, with no material shift in win rates despite narrowed risk corridors.


Evolent Health (EVH)-8 May 25-2025 Q1 Earnings call transcript

- **2025 Growth Confidence**: 15%-18% organic growth guided, backed by $115M EBITDA improvement from contract renegotiations.
- **Oncology Risk Mitigation**: 12% trend assumption conservative; 400bps margin recovery baked in, 300bps+ upside with stable trends.
- **Automation Payoff**: $50M+ annual savings by 2026, offsetting $10M 2025 implementation costs.
- **Client Loyalty**: 100% renewal rate for top clients, 1-year Centene extension with mutual value-sharing initiatives.
- **Pipeline Strength**: Multiple H1 2025 closings expected, including 1.9M-member tech/services deal.

**【CEO Summary Section】**
- **2024 Financial Highlights**: Revenue of $2.55 billion (+30% YoY), Adjusted EBITDA of $160.5 million. 2025 organic growth guidance of 15%-18%.
- **2025 Outlook**: Adjusted EBITDA range of $135 million to $165 million. $115 million EBITDA improvement from renegotiated Performance Suite contracts.
- **Client Retention**: 100% logo renewal rate for top customers (90%+ of revenue), including a 1-year Centene contract extension.
- **Pipeline Strength**: Strong sales pipeline with multiple deals expected to close in H1 2025, including a new 1.9 million-member tech/services contract.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Revenue $646.5 million, Adjusted Gross Margin 11.9%. Oncology Performance Suite margin -7% due to elevated costs.
- **2025 Guidance**: Organic growth 15%-18%, EBITDA $135M-$165M. $10M investment in AI automation to drive $50M+ annual savings by 2026.
- **Oncology Trend**: 12% YoY cost growth assumption (vs. historical 8%). 400bps margin recovery from renegotiated contracts, 300bps+ potential with stable trends.
- **Balance Sheet**: $104M cash (excluding $300M credit facility), net leverage 3.6x. 2025 convertible notes refinancing planned.

**【Q&A Key Themes】**
- **Trend Sensitivity**: 2% variance in oncology trend could swing EBITDA by $9M-$12M. 2025 guidance includes $45M headwinds (partner exits, trend).
- **Automation Impact**: $20M+ annualized cost savings by end-2025, $50M+ long-term. 2025 EBITDA drag of $10M from implementation costs.
- **Sales Momentum**: 100% renewal rate, strong pipeline in MSK, cardiology. New Performance Suite model with capped downside winning deals.
- **Policy Risks**: Medicaid FMAP cuts could impact enrollment, but diversified business (33% Medicaid, rest Medicare/commercial).

Actual												-0.14	-0.03	-0.03	-0.01	-0.01	0.0024	-0.03	0.08	0.12	0.1	0.59	0.1	0.21	0.14	0.3	0.23	0.34	0.3	0.04	-0.02	0.06	-0.1	0.05	0.08
Forecast												-0.1311	-0.0991	-0.044	-0.0463	-0.065	-0.0486	-0.0343	0.0083	-0.002	0.0486	0.1186	0.0977	0.1708	0.1549	0.103	0.1665	0.2411	0.2392	0.3095	0.0301	0.0939	0.0742	0.0979	0.0511
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.79%	+69.73%	+31.82%	+78.40%	+84.62%	+104.94%	+12.54%	+863.86%	+6100.00%	+105.76%	+397.47%	+2.35%	+22.95%	-9.62%	+191.26%	+38.14%	+41.02%	+25.42%	-87.08%	-166.45%	-36.10%	-234.77%	-48.93%	+56.56%

EVH

EVH fundamentals

EVH Q4 2025 Earnings

Earnings Call

You can ask Aime

EVH

EVH fundamentals

EVH Q4 2025 Earnings

Earnings Call

EVH Earnings Call Summary for Q4/20255:00 PM on Feb 24, 2026

EVH Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

EVH Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

EVH Earnings Call Summary for Q1/20255:00 PM on May 8, 2025

EVH Earnings Call Summary for Q4/20245:00 PM on Feb 20, 2025

You can ask Aime